Quelle |
1.) Vale CL, et al., for the STOpCaP Steering Group:
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer:
a systematic review and meta-analyses of aggregate data.
Lancet Oncol 2016;17):243–256. Doi: 10.1016/S1470-2045(15)00489-1
2.) Sweeney CJ, Chen Y-H, Carducci M:
Chemohormonal therapy in metastatic hormone-sensitive prostate cancer.
N Engl J Med. 2015;373:737–746
3. ) James ND, Sydes MR, Clarke NW:
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE):
survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
Lancet 2015 http://dx.doi.org/10.1016/S0140-6736(15)01037-5
4.) Gravis G, Fizazi K, Joly F:
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
Lancet Oncol. 2013;14:149–158
5.) Gravis G, Boher JM, Joly F:
Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-naïve metastatic prostate cancer (PCa):
long-term analysis of the GETUG-AFU 15 phase III trial.
Proc Am Soc Clin Oncol. 2015;33(suppl 7) abstr 140.
6.) Fizazi K, Laplanche A, Lesaunier F:
Docetaxel-estramustine in localized high-risk prostate cancer: results of the French Genitourinary Tumor Group GETUG 12 phase III trial.
Proc Am Soc Clin Oncol. 2014;32(suppl) abstr 5005.
7.) Fizazi K, Faivre L, Lesaunier F:
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12):
a phase 3 randomised controlled trial.
Lancet Oncol. 2015;16:787–794
8.) Schweizer MT, Huang P, Kattan MW, Kibel AS, De Wit R, Sternberg CN:
Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501).
Cancer. 2013;119:3610–3618
9.) Sandler HM, Hu C, Rosenthal SA:
A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT)
with doxetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521)
Proc Am Soc Clin Oncol. 2015;33(suppl) abstr LBA5022.
|